Valuation: Grace Therapeutics, Inc.

Market Cap 55.58M 39.13M 35.09M 32.34M 29.37M 3.67B 57.13M 387M 154M 1.97B 147M 144M 6.21B P/E 2027 *
-1.59x
P/E 2028 * -4.13x
Enterprise Value 55.58M 39.13M 35.09M 32.34M 29.37M 3.67B 57.13M 387M 154M 1.97B 147M 144M 6.21B EV / Sales 2027 *
-
EV / Sales 2028 * 8.12x
Free-Float
81.32%
Yield 2027 *
-
Yield 2028 * -
1 day-0.27%
1 week+1.09%
Current month-4.12%
1 month-10.58%
3 months-11.85%
6 months-20.51%
Current year-46.24%
1 week 1.75
Extreme 1.75
1.94
1 month 1.67
Extreme 1.67
2.07
Current year 1.67
Extreme 1.67
5.18
1 year 1.67
Extreme 1.67
5.18
3 years 1.67
Extreme 1.67
5.18
5 years 1.67
Extreme 1.67
10.74
10 years 1.67
Extreme 1.67
161.11
Manager TitleAgeSince
Chief Executive Officer 54 03/04/2023
Director of Finance/CFO 55 04/01/2024
Chief Tech/Sci/R&D Officer 65 07/05/2023
Director TitleAgeSince
Director/Board Member 59 09/10/2023
Director/Board Member 57 09/10/2023
Director/Board Member 63 09/10/2023
Date Insider Type Main position Quantity % Market Cap. Importance
05/11/26
Opaleye Management, Inc.
BuyCompany 3,087 0.0147%
26/10/26
Opaleye Management, Inc.
BuyCompany 66,411 0.3157%
19/10/26
Opaleye Management, Inc.
BuyCompany 4,256 0.0202%
Change 5-day change 1-year change 3-year change Capi.($)
-0.27%+1.09%-37.79%-16.36% 39.23M
+0.01%+11.10%+60.83%+70.43% 68.22B
+1.22%+9.56%+15.97%+90.23% 59.82B
+0.24%+1.35%+23.78%+97.55% 56.07B
+1.60%+19.44%+28.80%+112.95% 47.67B
-1.32%+4.78%+29.15%+40.40% 45.95B
-3.54%-0.60%+207.76%+879.50% 43.29B
-3.33%+6.90%+22.78%+48.07% 35.66B
-2.19%-3.71%+90.94%+66.33% 34.73B
+2.92%+14.41%-37.74%+403.12% 25.47B
Average -0.47%+5.18%+40.45%+179.22% 42B
Weighted average by Cap. -0.41%+5.50%+50.74%+180.54%

Financials

2027 *2028 *
Net sales - 6.84M 4.82M 4.32M 3.98M 3.61M 452M 7.03M 47.66M 18.99M 242M 18.07M 17.69M 765M
Net income -34.73M -24.45M -21.92M -20.21M -18.35M -2.29B -35.7M -242M -96.39M -1.23B -91.75M -89.8M -3.88B -16.92M -11.91M -10.68M -9.84M -8.94M -1.12B -17.39M -118M -46.95M -598M -44.69M -43.74M -1.89B
Net Debt - -
Projected Income Statement - Annual - Grace Therapeutics, Inc.
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
10/11/26 US$1.860 -0.27% 27,963
09/11/26 US$1.865 +0.81% 128,723
06/11/26 US$1.850 +3.93% 114,883
05/11/26 US$1.780 -1.66% 97,130
04/11/26 US$1.810 -1.63% 64,541
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Grace Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.642CAD
Average target price
8.342CAD
Spread / Average Target
+215.72%
  1. Stock Market
  2. Stocks
  3. GRCE Stock